These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 18248274)
1. Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction. Howlett JG Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):199-208. PubMed ID: 18248274 [TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and treatment of anemia in heart failure patients]. Santilli G; Tarantini L; Baio P; Senni M G Ital Cardiol (Rome); 2011 May; 12(5):319-26. PubMed ID: 21593950 [TBL] [Abstract][Full Text] [Related]
4. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487 [TBL] [Abstract][Full Text] [Related]
5. The interaction between heart failure and other heart diseases, renal failure, and anemia. Silverberg DS; Wexler D; Iaina A; Schwartz D Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468 [TBL] [Abstract][Full Text] [Related]
6. Anemia and chronic heart failure implications and treatment options. Anand IS J Am Coll Cardiol; 2008 Aug; 52(7):501-11. PubMed ID: 18687241 [TBL] [Abstract][Full Text] [Related]
7. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. Palazzuoli A; Silverberg DS; Calabrò A; Spinelli T; Quatrini I; Campagna MS; Franci B; Nuti R J Cardiovasc Pharmacol; 2009 Jun; 53(6):462-7. PubMed ID: 19455052 [TBL] [Abstract][Full Text] [Related]
8. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. McMurray JJ; Anand IS; Diaz R; Maggioni AP; O'Connor C; Pfeffer MA; Polu KR; Solomon SD; Sun Y; Swedberg K; Tendera M; van Veldhuisen DJ; Wasserman SM; Young JB; Eur J Heart Fail; 2009 Aug; 11(8):795-801. PubMed ID: 19633103 [TBL] [Abstract][Full Text] [Related]
9. [Anaemia in chronic heart failure]. Hradec J Vnitr Lek; 2010 Aug; 56(8):854-9. PubMed ID: 20845618 [TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agents and heart failure. Lipšic E; van der Meer P; van Veldhuisen DJ Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926 [TBL] [Abstract][Full Text] [Related]
11. [Current issues in erythropoietin therapy of renal anemia]. Zakar G Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596 [TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P; Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176 [TBL] [Abstract][Full Text] [Related]
13. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396 [TBL] [Abstract][Full Text] [Related]
15. Use of erythropoietin in heart failure management. Caiola K; Cheng JW Ann Pharmacother; 2004 Dec; 38(12):2145-9. PubMed ID: 15494385 [TBL] [Abstract][Full Text] [Related]
16. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703 [TBL] [Abstract][Full Text] [Related]
17. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? Silverberg DS; Wexler D; Iaina A J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047 [TBL] [Abstract][Full Text] [Related]
18. Anemia in chronic heart failure: can we treat? What to treat? von Haehling S; Anker MS; Jankowska EA; Ponikowski P; Anker SD Heart Fail Rev; 2012 Mar; 17(2):203-10. PubMed ID: 21979835 [TBL] [Abstract][Full Text] [Related]
19. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232 [TBL] [Abstract][Full Text] [Related]
20. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. Comín-Colet J; Ruiz S; Cladellas M; Rizzo M; Torres A; Bruguera J J Card Fail; 2009 Nov; 15(9):727-35. PubMed ID: 19879457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]